Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
The company’s lead product candidate, MOv18 IgE, is in a phase I clinical trial in folate receptor alpha positive cancer patients. This is the world’s first IgE drug to enter clinical trials. Epsilogen has constructed a novel and proprietary pipeline of anti-cancer IgE antibodies.